Reports

Sale

Inflammatory Bowel Disease Treatment Market

Inflammatory Bowel Disease Treatment Market Size, Share: By Treatment Type: Medications, Surgery, Others; By Disease Type: Ulcerative Colitis, Crohn's Disease, Colitis; By Dosage Form: Tablet, Capsule, Injectables, Others; By Route of Administration; By End User; By Distribution Channel; Regional Analysis; Competitive Landscape; 2024-2032

Inflammatory Bowel Disease Treatment Market Outlook

The inflammatory bowel disease treatment market size for the 7 major regions was valued at USD 19.6 billion in 2023, driven by the increasing incidence of inflammatory bowel disease across these major markets. The market is expected to grow at a CAGR of 5.71% during the forecast period of 2024-2032, with the values likely to rise from USD 20.7 billion in 2024 to USD 32.3 billion by 2032.

 

Global Inflammatory Bowel Disease Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Inflammatory Bowel Disease Treatment: Introduction

Inflammatory bowel disease is a set of two disorders (ulcerative colitis and Crohn’s disease) causing chronic inflammation in the digestive system (particularly intestines). Common symptoms include abdominal pain, diarrhea, appetite loss, bloating or blood in stool. Immune system malfunction and gene mutation may be general causes of the disease.

 

IBD treatment revolves around reducing inflammation. Medical professionals use anti-inflammatory drugs as a primary treatment source. Immune system suppressors, antibiotics, biologics, and surgery in extreme cases are common treatment methods.

 

Inflammatory Bowel Disease Treatment Market Analysis

With the rising prevalence of Crohn's disease and ulcerative colitis coupled with increasing government support for research, the market for IBD treatment has seen significant growth. Although the explicit etiopathogenesis of inflammatory bowel disease is still vague, researchers have been able to develop effective drugs and treatment alternatives with the help of greater understanding of the digestive physiology and technical advancements in biotechnology. This has fueled the inflammatory bowel disease treatment market growth further.

 

The increasing number of drugs under clinical trials and the rising popularity of pre-biotic and pro-biotic food products are likely to contribute to the market value. An antibody Mirikizumab (Omvoh) is currently in under trials for treatment IBD. It works by blocking proteins that trigger gut inflammation. The FDA approval for the drug is awaited.

 

To meet the rising inflammatory bowel disease treatment market demand, healthcare giants across the 7 major markets are undergoing significant mergers and acquisitions. For instance, in October 2023, Sanofi and Teva announced their exclusive partnership to deliver IBD treatment drugs. The collaboration combines Teva’s anti-TL1A therapy (developed to treat Crohn’s diseases and ulcerative colitis) to Sanofi’s immunology strategy for exploring the action mechanism of chronic inflammatory diseases. They aim at commercializing and developing the TEV’574 drug together, which is currently phase 2 trials.

 

In addition, Merck has also announced USD 10.8 billion worth buy-out of Prometheus Biosciences, in order to access their anti-TL1A monoclonal antibody (mAb) entering a Phase III placebo-controlled study for Crohn’s and ulcerative colitis (UC). This indicates that the inflammatory bowel disease treatment market value is going to expand further.

 

Global Inflammatory Bowel Disease Treatment Market By Drug

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Inflammatory Bowel Disease Treatment Market Segmentation

Market Breakup by Treatment Type

  • Medications 
    • Corticosteroids 
    • Aminosalicylates 
    • Biologics 
    • Immunosuppressants 
    • Antibiotics 
    • Others 
  • Surgery
  • Others

 

Market Breakup by Disease Type 

  • Ulcerative Colitis 
  • Crohn's Disease 
  • Colitis

 

Market Breakup by Dosage Form

  • Tablet
  • Capsule
  • Injectables 
  • Others

 

Market Breakup by Route of Administration

  • Oral 
  • Parenteral 
  • Others 

 

Market Breakup by End User

  • Hospitals 
  • Specialty Clinics 
  • Homecare Settings 
  • Others 

 

Market Breakup by Distribution Channel

  • Hospital Pharmacy 
  • Online Pharmacy 
  • Retail Pharmacy 

 

Market Breakup by Region- 7MM

  • United States 
  • EU-4 and the United Kingdom 
  • Japan 

 

Global Inflammatory Bowel Disease Treatment Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Inflammatory Bowel Disease Treatment Market Overview

The Asia Pacific region is poised to witness the fastest growth due to rising investments on building research and development infrastructure to leverage academic talent and offer better opportunities for developing quality treatments. Japan is one of the leading regions in terms of development and is likely to contribute significantly to the market growth.

 

Europe’s inflammatory bowel disease treatment market size is projected to grow exponentially, considering continuous government campaigns promoting early diagnosis of the disease. The Scottish government has launched an IBD awareness campaign to combat the rising cases. The EFCCA campaign is another example. Novel eHealth has also launched an AI-assisted eHealth platform called miGut-Health to monitor health status in patients.

 

Inflammatory Bowel Disease Treatment Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players in the 7 major regions. The major companies in the market are as follows:

 

  • Pfizer Inc. 
  • GlaxoSmithKline plc. 
  • Novartis AG 
  • Mylan N.V. 
  • Teva Pharmaceutical Industries Ltd. 
  • AstraZeneca Plc 
  • Janssen Pharmaceuticals (Johnson & Johnson)  
  • Merck & Co.,  
  • Baxter International Inc. 
  • Bayer AG 
  • Eli Lilly and Company 
  • Sun Pharmaceutical Industries Ltd. 
  • AbbVie Inc. 
  • Abbott Laboratories

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment Type
  • Disease Type
  • Dosage Form
  • Route of Administration
  • End User
  • Distribution Channel
  • Region
Breakup by Treatment Type
  • Medications
  • Surgery
  • Others
Breakup by Disease Type
  • Ulcerative Colitis
  • Crohn's Disease
  • Colitis
Breakup by Dosage Form
  • Tablet
  • Capsule
  • Injectables
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • AstraZeneca Plc
  • Janssen Pharmaceuticals (Johnson & Johnson) 
  • Merck & Co.,
  • Baxter International Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Abbott Laboratories

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Inflammatory Bowel Disease Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Inflammatory Bowel Disease Epidemiology Analysis – 7MM
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
        5.3.1    Germany Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
        5.3.2    France Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
        5.3.3    Italy Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
        5.3.4    Spain Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
    5.4    Japan Inflammatory Bowel Disease Epidemiology Forecast (2017-2032)
6    Inflammatory Bowel Disease Treatment Market Overview – 7MM
    6.1    Inflammatory Bowel Disease Treatment Market Historical Value (2017-2023) 
    6.2    Inflammatory Bowel Disease Treatment Market Forecast Value (2024-2032)
7    Inflammatory Bowel Disease Treatment Market Landscape – 7MM
    7.1    Global Inflammatory Bowel Disease Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global Inflammatory Bowel Disease Treatment Product Landscape
        7.2.1    Analysis by Treatment Type
        7.2.2    Analysis by Route of Administration
        7.2.3    Analysis by End User
8    Inflammatory Bowel Disease Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Inflammatory Bowel Disease Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Inflammatory Bowel Disease Treatment Market Segmentation – 7MM
    11.1    Inflammatory Bowel Disease Treatment Market by Treatment Type
        11.1.1    Market Overview
        11.1.2    Medications
            11.1.2.1    Corticosteroids
            11.1.2.2    Aminosalicylates
            11.1.2.3    Biologics
            11.1.2.4    Immunosuppressants
            11.1.2.5    Antibiotics
            11.1.2.6    Others
        11.1.3    Surgery
        11.1.4    Others
    11.2    Inflammatory Bowel Disease Treatment Market by Disease Type
        11.2.1    Market Overview
        11.2.2    Ulcerative Colitis
        11.2.3    Crohn's Disease
        11.2.4    Colitis
    11.3    Inflammatory Bowel Disease Treatment Market by Dosage Form
        11.3.1    Market Overview
        11.3.2    Tablet
        11.3.3    Capsule
        11.3.4    Injectables
        11.3.5    Others
    11.4    Inflammatory Bowel Disease Treatment Market by Route of Administration
        11.4.1    Market Overview
        11.4.2    Oral
        11.4.3    Parenteral
        11.4.4    Others
    11.5    Inflammatory Bowel Disease Treatment Market by End User
        11.5.1    Market Overview
        11.5.2    Hospitals
        11.5.3    Specialty Clinics
        11.5.4    Homecare Settings
        11.5.5    Others
    11.6    Inflammatory Bowel Disease Treatment Market by Distribution Channel
        11.6.1    Market Overview
        11.6.2    Hospital Pharmacy
        11.6.3    Online Pharmacy
        11.6.4    Retail Pharmacy
    11.7    Inflammatory Bowel Disease Treatment Market by Region
        11.7.1    Market Overview
        11.7.2    United States
        11.7.3    EU-4 and the United Kingdom
            11.7.3.1    Germany
            11.7.3.2    France
            11.7.3.3    Italy
            11.7.3.4    Spain
            11.7.3.5    United Kingdom    
        11.7.4    Japan
12    United States Inflammatory Bowel Disease Treatment Market
    12.1    Inflammatory Bowel Disease Treatment Market Historical Value (2017-2023) 
    12.2    Inflammatory Bowel Disease Treatment Market Forecast Value (2024-2032)
    12.3    Inflammatory Bowel Disease Treatment Market by Disease Type
    12.4    Inflammatory Bowel Disease Treatment Market by Treatment Type
13    EU-4 and United Kingdom Inflammatory Bowel Disease Treatment Market
    13.1    Inflammatory Bowel Disease Treatment Market Historical Value (2017-2023) 
    13.2    Inflammatory Bowel Disease Treatment Market Forecast Value (2024-2032)
    13.3    Germany Inflammatory Bowel Disease Treatment Market Overview
        13.3.1    Inflammatory Bowel Disease Treatment Market by Disease Type
        13.3.2    Inflammatory Bowel Disease Treatment Market by Treatment Type
    13.4    France Inflammatory Bowel Disease Treatment Market Overview
        13.4.1    Inflammatory Bowel Disease Treatment Market by Disease Type
        13.4.2    Inflammatory Bowel Disease Treatment Market by Treatment Type
    13.5    Italy Inflammatory Bowel Disease Treatment Market Overview
        13.5.1    Inflammatory Bowel Disease Treatment Market by Disease Type
        13.5.2    Inflammatory Bowel Disease Treatment Market by Treatment Type
    13.6    Spain Inflammatory Bowel Disease Treatment Market Overview
        13.6.1    Inflammatory Bowel Disease Treatment Market by Disease Type
        13.6.2    Inflammatory Bowel Disease Treatment Market by Treatment Type
    13.7    United Kingdom Inflammatory Bowel Disease Treatment Market Overview
        13.7.1    Inflammatory Bowel Disease Treatment Market by Disease Type
        13.7.2    Inflammatory Bowel Disease Treatment Market by Treatment Type
14    Japan Inflammatory Bowel Disease Treatment Market
    14.1    Inflammatory Bowel Disease Treatment Market Historical Value (2017-2023) 
    14.2    Inflammatory Bowel Disease Treatment Market Forecast Value (2024-2032)
    14.3    Inflammatory Bowel Disease Treatment Market by Disease Type
    14.4    Inflammatory Bowel Disease Treatment Market by Treatment Type
15    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    JAPAN PMDA
16    Patent Analysis
    16.1    Analysis by Type of Patent
    16.2    Analysis by Publication year
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Patent Age
    16.5    Analysis by CPC Analysis
    16.6    Analysis by Patent Valuation 
    16.7    Analysis by Key Players
17    Grants Analysis
    17.1    Analysis by year
    17.2    Analysis by Amount Awarded
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Grant Application
    17.5    Analysis by Funding Institute
    17.6    Analysis by NIH Departments
    17.7    Analysis by Recipient Organization 
18    Clinical Trials Analysis
    18.1     Analysis by Trial Registration Year
    18.2    Analysis by Trial Status
    18.3    Analysis by Trial Phase
    18.4    Analysis by Therapeutic Area
    18.5    Analysis by Geography
19    Funding and Investment Analysis
    19.1    Analysis by Funding Instances
    19.2    Analysis by Type of Funding
    19.3    Analysis by Funding Amount
    19.4    Analysis by Leading Players
    19.5    Analysis by Leading Investors
    19.6    Analysis by Geography
20    Partnerships and Collaborations Analysis
    20.1    Analysis by Partnership Instances
    20.2    Analysis by Type of Partnership
    20.3    Analysis by Leading Players
    20.4    Analysis by Geography
21    Supplier Landscape
    21.1    Pfizer Inc.
        21.1.1    Financial Analysis
        21.1.2    Product Portfolio
        21.1.3    Demographic Reach and Achievements
        21.1.4    Mergers and Acquisitions
        21.1.5    Certifications
    21.2    GlaxoSmithKline plc.
        21.2.1    Financial Analysis
        21.2.2    Product Portfolio
        21.2.3    Demographic Reach and Achievements
        21.2.4    Mergers and Acquisitions
        21.2.5    Certifications
    21.3    Novartis AG
        21.3.1    Financial Analysis
        21.3.2    Product Portfolio
        21.3.3    Demographic Reach and Achievements
        21.3.4    Mergers and Acquisitions
        21.3.5    Certifications
    21.4    Mylan N.V.
        21.4.1    Financial Analysis
        21.4.2    Product Portfolio
        21.4.3    Demographic Reach and Achievements
        21.4.4    Mergers and Acquisitions
        21.4.5    Certifications
    21.5    Teva Pharmaceutical Industries Ltd.
        21.5.1    Financial Analysis
        21.5.2    Product Portfolio
        21.5.3    Demographic Reach and Achievements
        21.5.4    Mergers and Acquisitions
        21.5.5    Certifications
    21.6    Sanofi SA
        21.6.1    Financial Analysis
        21.6.2    Product Portfolio
        21.6.3    Demographic Reach and Achievements
        21.6.4    Mergers and Acquisitions
        21.6.5    Certifications
    21.7    AstraZeneca Plc
        21.7.1    Financial Analysis
        21.7.2    Product Portfolio
        21.7.3    Demographic Reach and Achievements
        21.7.4    Mergers and Acquisitions
        21.7.5    Certifications
    21.8    Janssen Pharmaceuticals (Johnson & Johnson) 
        21.8.1    Financial Analysis
        21.8.2    Product Portfolio
        21.8.3    Demographic Reach and Achievements
        21.8.4    Mergers and Acquisitions
        21.8.5    Certifications
    21.9    Merck & Co., 
        21.9.1    Financial Analysis
        21.9.2    Product Portfolio
        21.9.3    Demographic Reach and Achievements
        21.9.4    Mergers and Acquisitions
        21.9.5    Certifications
    21.10    Baxter International Inc.
        21.10.1    Financial Analysis
        21.10.2    Product Portfolio
        21.10.3    Demographic Reach and Achievements
        21.10.4    Mergers and Acquisitions
        21.10.5    Certifications
    21.11    Bayer AG
        21.11.1    Financial Analysis
        21.11.2    Product Portfolio
        21.11.3    Demographic Reach and Achievements
        21.11.4    Mergers and Acquisitions
        21.11.5    Certifications
    21.12    Eli Lilly and Company
        21.12.1    Financial Analysis
        21.12.2    Product Portfolio
        21.12.3    Demographic Reach and Achievements
        21.12.4    Mergers and Acquisitions
        21.12.5    Certifications
    21.13    Sun Pharmaceutical Industries Ltd.
        21.13.1    Financial Analysis
        21.13.2    Product Portfolio
        21.13.3    Demographic Reach and Achievements
        21.13.4    Mergers and Acquisitions
        21.13.5    Certifications
    21.14    AbbVie Inc.
        21.14.1    Financial Analysis
        21.14.2    Product Portfolio
        21.14.3    Demographic Reach and Achievements
        21.14.4    Mergers and Acquisitions
        21.14.5    Certifications
    21.15    Abbott Laboratories
        21.15.1    Financial Analysis
        21.15.2    Product Portfolio
        21.15.3    Demographic Reach and Achievements
        21.15.4    Mergers and Acquisitions
        21.15.5    Certifications
22    Inflammatory Bowel Disease Treatment Market- Distribution Model (Additional Insight)
    22.1    Overview 
    22.2    Potential Distributors 
    22.3    Key Parameters for Distribution Partner Assessment 
23    Key Opinion Leaders (KOL) Insights (Additional Insight)
24    Company Competitiveness Analysis (Additional Insight)

    24.1    Very Small Companies
    24.2    Small Companies
    24.3    Mid-Sized Companies
    24.4    Large Companies
    24.5    Very Large Companies
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 19.6 billion in 2023, driven by the rising incidence of inflammatory bowel disease across these regions.

The market is anticipated to grow at a CAGR of 5.71% during the forecast period of 2024-2032, likely to reach a market value of USD 32.3 billion by 2032.

With a greater understanding of digestive physiology and technological advancements in biotechnology, there has been significant developments in IBD drugs. This has led to a surge in the market demand.

Major trends include mergers and acquisitions among prominent healthcare providers. For example, Sanofi and Teva announced their exclusive partnership to deliver an IBD treatment drug called TEV’574.

The major regions of the market include the United States, Japan, EU-4, and the United Kingdom.

Common treatments include medications such as corticosteroids, aminosalicylates, biologics, immunosuppressants, antibiotics, surgery, and others.

Tablets, capsules, injectables and others are common dosage forms.

It is divided into ulcerative colitis, Crohn's disease, and colitis.

The route of administration can be oral, parenteral, or others.

Major end users include hospitals, speciality clinics, homecare settings and others.

Major distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others.

Key players involved in the market are Pfizer Inc., GlaxoSmithKline plc., Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., AstraZeneca Plc, Janssen Pharmaceuticals (Johnson & Johnson), Merck & Co., Baxter International Inc., Bayer AG, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., AbbVie Inc., and Abbott Laboratories.

Purchase Full Report

Mini Report

$ 3299     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 6599     $5999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8799     $7999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9899     $8999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER